MedPath

Polycan in Combination With Glucosamine for Treatment of Knee Osteoarthritis

Not Applicable
Completed
Conditions
Osteoarthritis of the Knee
Registration Number
NCT03717714
Lead Sponsor
Vietstar Biomedical Research
Brief Summary

The objectives of this study is to examine the Safety and Efficacy of black yeast beta-glucan produced from Aureobusidium pulluluns SM-2001 (Polycan), in combination with glucosamine in reducing knee osteoarthritis (OA) associated symptoms. This study is a double-blind, randomized, active-controlled trial conducted with 100 OA patients, aged 35-80 years using a formulated product

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Confirmed diagnosis of knee osteoarthritis (OA)
  • OA ranging from grade 1 to grade 3 by Kellgren and Lawrence system
  • Agree to participate into the study
Exclusion Criteria
  • OA ranging from grade 4 by Kellgren and Lawrence system
  • Allergic or contradicted with oral NSAIDs (Meloxicam)
  • Pregnant and breastfeeding women.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) changes at 12 weeks in the three groupsBaseline to Week 12

The WOMAC consists of 24 items divided into 3 subscales:

Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing Stiffness (2 items): after first waking and later in the day Physical Function (17 items): stair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties.

Total WOMAC score ranges from 0 to 96 with higher scores indicate worse pain, stiffness, and functional limitations

Secondary Outcome Measures
NameTimeMethod
Number of dose of rescue medication (Meloxicam 7.5mg) used in the three groups.Through study completion, an average of 12 weeks

Rescue medication (Meloxicam 7.5mg) used by patients for 12 weeks

Trial Locations

Locations (1)

198 Hospital

🇻🇳

Hanoi, Vietnam

198 Hospital
🇻🇳Hanoi, Vietnam

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.